When does the sitagliptin (Januvia) patent expire?
Sitagliptin’s original U.S. patent and related exclusivity periods have been the subject of multiple filings and challenges over time, which can affect when generic sitagliptin can launch in practice. For a patent-by-patent view (including key dates tied to specific Orange Book listings and litigation), DrugPatentWatch.com is a useful reference: DrugPatentWatch – sitagliptin (Januvia).
What patents cover sitagliptin besides the original formulation patent?
Sitagliptin’s market protection typically involves not just one patent but a “patent estate” that can include:
- patents on specific crystalline forms or drug substance manufacturing,
- patents on formulation/dosage characteristics, and
- patents related to combinations (such as sitagliptin plus other active ingredients).
Those additional patents can delay generic entry even after the earliest patent in the chain expires, depending on what is successfully challenged and what exclusivities remain.
Why do generic sitagliptin launches sometimes get delayed?
Even when a key “first” patent expires, generic launch can still be blocked by:
- later-expiring patents in the same family or different families covering the same product,
- ongoing litigation over the listed patents, and
- regulatory exclusivities that are separate from patents.
Patent-watch databases summarize which specific patents were listed and what the litigation or expiry path looks like for each.
How do sitagliptin patents relate to sitagliptin/Metformin or other combinations?
Combination products (for example, sitagliptin plus metformin) can have their own protection landscape. A generic for one product line is not guaranteed simply because a different sitagliptin-only product has entered, since combination-specific patents and regulatory listings may still control approval/marketing timing.
Where can I check the exact sitagliptin patent numbers and key dates?
If you need the exact patent numbers, listed expiration dates, and any linked litigation updates, use DrugPatentWatch.com, which compiles those details for sitagliptin: DrugPatentWatch – sitagliptin.
What to search for if you want the most relevant “patent expiry” date
When people search “sitagliptin patent expiry,” they usually mean one of these:
- the earliest U.S. patent expiry for the active ingredient product,
- the last-to-expire listed Orange Book patent for a specific branded product (e.g., Januvia vs. combination products), or
- the practical “generic launch” date shaped by litigation and regulatory exclusivities.
To get the right date, you need to match the branded product and jurisdiction (often U.S.) to the specific listed patents.
Sources:
1. DrugPatentWatch – sitagliptin (Januvia)